Last Update 18 Mar 26

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.
Updated 2026 guidance is seen as a key anchor for investor positioning, giving bulls a concrete framework to assess how execution could support the current price target.
Positive sentiment around the diagnostic tools peer group, with a focus on companies that present multiple avenues for upside to what analysts describe as derisked growth assumptions, keeps Azenta on the radar for investors who prioritize visibility.
The emphasis on multi year frameworks suggests analysts are willing to look beyond near term noise and focus on how consistent execution could support the current valuation range.

Bearish Takeaways

Bearish analysts have trimmed price targets by mid single digit amounts, indicating concerns that prior models may have been too optimistic once updated discount rates and growth assumptions are applied.
The combination of recent target cuts and the current US$39 level suggests some caution around how quickly management can deliver against 2026 guidance, especially if execution slips.
References to derisked growth assumptions imply that some analysts see limited room for error, and any shortfall versus the multi year plan could pressure the stock’s valuation.
Hold level ratings in recent research signal that a portion of the Street is taking a wait and see stance, looking for more evidence that the company can fully capitalize on the identified avenues for upside.

What's in the News

Partnered with Frontier Space to run life sciences experiments in microgravity, using Azenta consumables on the EGGS-2 mission to test performance of the SpaceLab Mk 2 research platform under real launch and spaceflight conditions (Key Developments).
Supplied 42 passive experimental samples using FluidX 0.26 mL tubes that were selected for reliability and durability in extreme conditions, with a focus on maintaining sample integrity in space-based research (Key Developments).
Used thermal sensors and active thermal management systems on the EGGS-2 payload to monitor temperature and thermal cycling in real time, aiming to understand how the space environment affects biological samples and next generation workflows (Key Developments).
Reiterated earnings guidance for full year fiscal 2026, with total organic revenue expected to grow in the range of 3% to 5% relative to fiscal 2025 (Key Developments).
Reported no share repurchases from December 8, 2025 to February 4, 2026 under the buyback program announced on December 10, 2025, with the tranche completed at 0 shares and US$0 million (Key Developments).

Valuation Changes

Fair Value remained steady at about $38.67, reflecting no change between the prior and updated estimates.
The Discount Rate edged lower from 7.89% to 7.88%, a very small adjustment to the rate used to value future cash flows.
Revenue Growth moved from 5.76% to 6.08%, indicating a modestly higher assumed growth rate for future $ revenue.
Net Profit Margin was adjusted slightly from 5.69% to 5.64%, a minor reduction in expected profitability on $ revenue.
Future P/E was effectively unchanged, with the multiple moving marginally from 55.82x to 55.79x in the updated model.

0 views

Key Takeaways

Strong growth driven by personalized medicine, automation, and outsourcing trends, with recurring revenue and margin expansion from stable pricing and digital modernization.
Operational efficiency, strategic investments, and disciplined portfolio management are fueling both cost control and sustainable long-term earnings resilience.
Delayed orders, market transitions, and rising costs amid industry pressures threaten Azenta's revenue growth, profitability, and long-term market opportunities.

Catalysts

About Azenta

Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.What are the underlying business or industry changes driving this perspective?

The accelerating shift toward personalized medicine and genetic research is driving sustained double-digit volume growth in next-generation sequencing (NGS) services for Azenta, supported by stable pricing and increased adoption among both academic and pharmaceutical clients. This underpins robust recurring revenue growth and expands the company's addressable market.
The ongoing trend of life sciences digitization and automation is reflected in Azenta's improved operational execution and introduction of more automated solutions; these efficiency gains, alongside investments in R&D and product management, are producing significant gross margin and EBITDA margin expansion, pointing to further net margin improvements with scale.
Increasing outsourcing of sample storage and biobanking is evident as customers face budget pressures, with Azenta securing new MSAs that deliver both cost savings and quality to core labs and pharma accounts. This positions the company to grow its recurring service revenue base and benefit from industry-wide life sciences outsourcing trends, supporting long-term earnings resilience.
Strategic investments in expanding sales force, regional commercial alignment, and targeted M&A (focused on core automation and biorepository solutions) are expected to accelerate organic and inorganic growth, while disciplined portfolio diversification into higher-margin services drives better operating leverage and earnings accretion.
The company's streamlined cost structure, as a result of structural realignment and deployment of the Azenta Business System (ABS), has already yielded substantial G&A reductions and improved working capital, which together enable sustainable free cash flow generation and margin stability even amid near-term macro headwinds.

Azenta Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Azenta's revenue will decrease by 0.8% annually over the next 3 years.
Analysts assume that profit margins will increase from -25.1% today to 5.0% in 3 years time.
Analysts expect earnings to reach $34.5 million (and earnings per share of $0.72) by about September 2028, up from $-167.5 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 54.2x on those 2028 earnings, up from -8.0x today. This future PE is greater than the current PE for the US Life Sciences industry at 29.1x.
Analysts expect the number of shares outstanding to grow by 0.56% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Azenta Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent customer budget constraints and internal realignments in the pharma and biotech sectors are causing delays in orders for Azenta's higher-margin capital equipment and core product lines, which risks slower revenue growth and potential volatility in top-line results.
Ongoing softness in Gene Synthesis and Sanger Sequencing revenues-exacerbated by project deprioritization at key pharma accounts and industry-wide transitions to newer sequencing technologies-may create long-term pressure on both total revenues and gross margins if not fully offset by new products or services.
The company's continued reliance on favorable product mix and operational cost improvements for gross margin expansion may become unsustainable if macro headwinds persist, competitive dynamics intensify, or if high-margin consumables and services growth slows, all of which could negatively impact future net margins and earnings.
Significant ongoing investments in R&D, sales, and infrastructure are required to drive innovation and growth; should improvements in top-line growth not materialize, these elevated expenses risk compressing net margins and free cash flow over the long term.
Reductions or inconsistent growth in government research funding (e.g., NIH grants), industry consolidation, and potential advances in sample preservation technology could reduce demand for outsourced sample management and services, negatively affecting both Azenta's addressable market and its long-term revenue trajectory.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $33.0 for Azenta based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $30.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $684.6 million, earnings will come to $34.5 million, and it would be trading on a PE ratio of 54.2x, assuming you use a discount rate of 7.2%.
Given the current share price of $29.37, the analyst price target of $33.0 is 11.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Azenta?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026